Thulium laser resection via a flexible cystoscope for recurrent non-muscle-invasive bladder cancer: Initial clinical experience

BJU International

Volumn 102, Issue 9, 2008, Pages 1115-1118

  Gao, Xu ^a   Ren, Shancheng ^a   Xu, Chuanliang ^a   Sun, Yinghao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bladder neoplasm; Flexible cystoscopy; Resection; Thulium laser

Indexed keywords

THULIUM;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTOSCOPY; FOLLOW UP; HUMAN; LASER; LASER SURGERY; OPERATION DURATION; PRIORITY JOURNAL; SURGICAL EQUIPMENT; SURGICAL TECHNIQUE; THULIUM LASER RESECTION; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; URINALYSIS;

AGED; CYSTOSCOPY; FEMALE; HUMANS; LASER THERAPY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; THULIUM; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 53849115041     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07814.x     Document Type: Article

References (20)

1. Malkowicz SB. Management of superficial bladder cancer. In Walsh PC, Retik AB, Vaughan ED eds, Campbell's Urology, 8th edn. Philadelphia, PA : WB Saunders, 2002 : 2785 802
2. Sobin DH, Wittekind Ch. TNM Classification of Malignant Tumours, 6th edn. New York : Wiley-Liss, 2002 : 199 202
3. German K, Hasan ST, Derry C. Cystodiathermy under local anaesthesia using the flexible cystoscope. Br J Urol 1992 69 : 518 20
4. Syed HA, Biyani CS, Bryan N, Brough SJ, Powell CS. Holmium:YAG laser treatment of recurrent superficial bladder carcinoma: initial clinical experience. J Endourol 2001 15 : 625 7
5. Morten M, Jonler L, Bisballe S. Holmium:YAG laser vaporization of recurrent papillary tumours of the bladder under local anaesthesia. BJU Int 2004 94 : 322 5
6. Fried NM, Murray KE. High-power thulium fiber laser ablation of urinary tissues at 1.94 mm. J Endourol 2005 19 : 25 31
7. Bach T, Herrmann TR, Cellarius C, Gross AJ. Bladder neck incision using a 70 W 2 micron continuous wave laser (RevoLix). World J Urol 2007 25 : 263 7
8. Soler-Martinez J, Vozmediano-Chicharro R, Morales-Jimenez P et al. Holmium laser treatment for low grade, low stage, noninvasive bladder cancer With local anesthesia and early instillation of mitomycin C. J Urol 2007 12 : 2337 9
9. Beisland HO, Seland O. A prospective randomized study on neodymium: YAG laser irradiation versus TUR in the treatment of urinary bladder cancer. Scand J Urol Nephrol 1986 20 : 209 12
10. Beer M, Jocham D, Beer A, Staehler G. Adjuvant laser treatment of bladder cancer: 8 years' experience with the Nd: YAG laser 1064 nm. Br J Urol 1989 63 : 476 8
11. Paul K, Pietrow Joseph A, Smith JR. Laser treatment for invasive and noninvasive carcinoma of the bladder. J Endourol 2001 15 : 415 8
12. Schomacker KT, Domankevitz Y, Flotte TJ et al. Co:MgF2 laser ablation of tissue: effect of wavelength on ablation threshold and thermal damage. Lasers Surg Med 1991 1 : 141 51
13. Fried NM. High-power laser vaporization of the canine prostate using a 110 W thulium fiber laser at 1.91 um. Lasers Surg Med 2005 36 : 52 6
14. Jou YC, Shen JH, Cheng MC, Lin CT, Chen PC. Percutaneous nephrolithotomy with holmium:yttrium-alumium- garnet laser and fiber guider - report of 349 cases. Urology 2005 65 : 454 8
15. Kay SL, Oz MC, Haber M, Blitzer A, Treat MR, Trokel SL. Soft tissue effects of the THC:YAG laser on canine vocal cords. Otolaryngol Head Neck Surg 1992 107 : 438 43
16. Silkiss RZ, Axelrod RN, Iwach AG, Vassiliadis A, Hennings DR. Transcanalicular THC:YAG dacryocystorhinostomy. Ophthalmic Surg 1992 23 : 351 3
17. Silkiss RZ. THC:YAG nasolacrimal duct recanalization. Ophthalmic Surg 1993 24 : 772 4
18. Devos D, Creac'h C, Laureau E, Bourriez JL, Guieu JD. Thulium laser evoked potentials. Normative values for the arms and legs. Neurophysiol Clin 2000 30 : 313 22
19. Smith JA Jr. Endoscopic applications of laser energy. Urol Clin North Am 1986 13 : 405 19
20. Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006 49 : 466 77